Cochlear Stock Earnings Reports

Key points for investors:

- FY25 results: group revenue modestly up (reported ~4%); cochlear implants performed well (units +9%, systems revenue +12%), acoustics mixed (Osia +30%, Baha softer) and services were the weak spot (services revenue down ~10%). Net profit was roughly flat (1% reported) and dividend maintained.

- Guidance: FY26 revenue guidance A$435–460m (11–17% reported); excluding last year’s cloud spend the underlying growth guidance is ~5–11%. Management expects developed-market CI unit growth >10% and a second-half weighting to FY26 (Nexa roll-out and related timing).

- Strategy & product drivers: management is prioritising sustained R&D and growth investment despite the near-term sales shortfall. Nexa (launched globally; FDA rollout in July) is presented as a material product step — smallest/full-day-processor, MAP-on-implant (Smart Sync), upgradable firmware and potential future stimulation modes and diagnostics. Kanso 3 and drug-eluting electrode pivotal trials are other product catalysts.

- Margin & cost dynamics: gross margin was ~74% (down ~1ppt) driven by mix shift to lower‑margin emerging markets and scaling Chengdu manufacturing (implant production ramp). R&D spend was preserved and will be slightly higher in FY26, meaning margins will trend toward but may be a little below 18% while investments continue. Management will report the remaining transformation/cloud program as a significant item from FY26.

- Investments & cash: transformation/cloud program total ~A$250m; ~A$130m of that expected in FY26–FY27 (pre-tax). Working capital increased (~A$200m YoY) driven by inventory build for new launches and safety stock; operating cash flow was weaker in FY25 due to working capital timing.

- Market & risks: China volume-based pricing (VBP) is boosting lower-tier volume but is a near-term revenue and margin headwind; services/upgrades in the U.S. showed weakness (consumer hesitation/co-pay pressure and cost-of-living impacts). Management is cautious on services near-term but expects single-digit services growth in FY26. Other risks include timing of government tenders and uncertainty around some grant/collaboration income.

- Execution items to monitor: Nexa uptake and pricing/contracting outcomes (especially in the U.S.), services/upgrade recovery (installed base behaviour), Chengdu margin ramp, transformation/cloud spend execution and the outcomes of early Nexa stimulation/diagnostic studies and drug-eluting electrode pivotal trials.